Agenus (NASDAQ:AGEN) Downgraded by Baird R W to “Hold”

Baird R W lowered shares of Agenus (NASDAQ:AGEN) from a strong-buy rating to a hold rating in a report released on Friday morning, Zacks.com reports.

AGEN has been the topic of several other reports. HC Wainwright lowered shares of Agenus from a buy rating to a neutral rating and cut their price objective for the company from $40.00 to $9.00 in a report on Thursday, July 18th. StockNews.com assumed coverage on Agenus in a research report on Wednesday, April 17th. They issued a hold rating on the stock. Robert W. Baird downgraded Agenus from an outperform rating to a neutral rating and dropped their price objective for the company from $35.00 to $8.00 in a report on Friday. Jefferies Financial Group reissued a hold rating and issued a $7.00 target price (up previously from $3.00) on shares of Agenus in a research note on Friday. Finally, William Blair lowered Agenus from an outperform rating to a market perform rating in a research report on Thursday, July 18th. Six analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of Hold and a consensus target price of $31.00.

Agenus Stock Up 14.4 %

AGEN stock opened at $6.85 on Friday. Agenus has a twelve month low of $4.78 and a twelve month high of $32.80. The company has a market cap of $143.85 million, a P/E ratio of -0.53 and a beta of 1.32. The business has a fifty day moving average of $14.24 and a 200-day moving average of $12.76.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($3.04) earnings per share for the quarter, topping the consensus estimate of ($3.58) by $0.54. The firm had revenue of $28.01 million for the quarter, compared to the consensus estimate of $40.70 million. As a group, equities research analysts anticipate that Agenus will post -9.7 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Agenus by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 558,606 shares of the biotechnology company’s stock valued at $324,000 after purchasing an additional 13,604 shares in the last quarter. PCG Wealth Advisors LLC boosted its holdings in shares of Agenus by 65.7% in the fourth quarter. PCG Wealth Advisors LLC now owns 47,550 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 18,850 shares during the period. Values First Advisors Inc. increased its position in shares of Agenus by 7.8% during the fourth quarter. Values First Advisors Inc. now owns 269,829 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 19,568 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Agenus by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 107,019 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 27,137 shares during the period. Finally, Crestline Management LP lifted its position in Agenus by 6.5% in the 4th quarter. Crestline Management LP now owns 708,480 shares of the biotechnology company’s stock valued at $587,000 after acquiring an additional 43,480 shares in the last quarter. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.